Co-Director, Center for Applied Proteomics and Molecular Medicine University Professor, George Mason University
Tom- very exciting to collaborate with you on this important study and the APOLLO program. There are very provocative results from the work IMO: - most notably the HRD work and the BMI-1 finding you uncovered- a potential new therapeutic target for HRP tumors (and potential synergy with PARPi) and for patients with overall worse prognosis! - that LMD enrichment of tumor epithelium may improve the coverage of neoepitopes that suggests that this workflow may better support personalized T-cell immunotherapy workflows - the verification that historical expression-based tumor types are largely reflective of tumor purity and that multiple prognostically relevant proteins are actually stromal in origin.: MES subtype are really just tumors that have a lot of stroma but at the molecular level they are DIF… - That bulk-tumor based analysis missed important biology and targetable candidates: these bulk tumor-based inputs have underpinned many well-known studies and beg the question: what did they miss? A lot perhaps….as they say “you don’t know what you don’t know” I am glad the field is finally starting to recognize the value and really necessity of upfront cellular enrichment prior to these comprehensive molecular profiling studies.
Interested in the ovarian cancer tumor tissue microenvironment? Check out our use of laser microdissection and deep proteogenomics of the ovarian cancer tissue microenvironment that revealed new clinically relevant insights...at cohort scale. More to come from the Applied Proteogenomic Organizational Learning and Outcomes (APOLLO) research network! Videobyte: https://lnkd.in/dYf8TfnF Article: https://lnkd.in/d76BwGm8 #ovariancancer #proteogenomics #multiomics #cancermoonshot #APOLLO #APOLLO2 #massspectrometry #teamscience #lasermicrodissection #Inovahealthsystem #USUHS #HJF
Director of Women's Health Research at Inova Women's Service Line
7moYes! Very well said Chip ^^^